Thymosin Alpha-1Thymosin Alpha-1
A synthetic version of a thymic peptide with country-specific approvals and mixed clinical evidence across settings.
Answer a short online consultation. A clinician reviews it, and you only pay if treatment is approved. Dispensed by our licensed facility.
What it is
Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic preparations; its synthetic medicinal form is called thymalfasin. It is different from thymosin beta-4.
Its pharmacology involves immune-cell signalling, including dendritic-cell and T-cell responses. Immune modulation is context-dependent and is not equivalent to reliably improving immunity in healthy people.
Why people ask about it
Interest often centres on immune resilience and healthy ageing, although these broad goals are not validated clinical indications.
What the science says
Thymalfasin has approvals in some countries for particular indications, including hepatitis-related uses; local authorisations differ. Trials in sepsis and other clinical settings have produced heterogeneous findings, which do not establish a general wellness benefit or UK or US approval.
Is it right for me?
An online consultation and clinician approval are necessary before payment for thymosin alpha-1, with local licensing and any immune-related diagnosis considered explicitly.
How Welcuren works
Complete a short online consultation about your health and goals.
A clinician reviews your answers, may ask follow-up questions, and decides whether this treatment is appropriate for you.
You only pay once treatment is approved. Our licensed facility then dispatches it with full instructions, on tracked global delivery.
Safety
Injection-site reactions and hypersensitivity are possible. Organ transplantation, immunosuppressant use, autoimmune illness, pregnancy and breastfeeding require specialist consideration because immune modulation may be undesirable; your clinician will advise
Questions
Is thymalfasin another name for this molecule?
Thymalfasin is the synthetic medicinal form of thymosin alpha-1.
Does approval overseas mean approval everywhere?
Authorisation is jurisdiction- and indication-specific, so overseas use does not establish local approval.
Is this the same peptide as TB-500?
Thymosin alpha-1 and thymosin beta-4 have different sequences and biological roles.
Do hospital studies show a healthy-ageing benefit?
Results in seriously ill populations cannot establish longevity or resilience outcomes in otherwise healthy adults.
This information is educational and not a substitute for advice from your clinician. Prescription treatments are only supplied after a clinical consultation.
Often considered together
Many clients start with a blood test so their clinician has a full picture.
ARA-290 (Cibinetide) 10mgARA-290 (Cibinetide) 10mg
ARA-290 (Cibinetide) 10mg is an investigational erythropoietin-derived peptide, considered only after online consultation and clinician approval.
BPC-157 + TB-500 Blend 10mgBPC-157 + TB-500 Blend 10mg
A two-component blend without controlled human evidence that the combination improves recovery or offers added benefit.
BPC-157 5mgBPC-157 5mg
A synthetic 15-amino-acid peptide with predominantly rodent evidence and no established clinical benefit for injury recovery.